VERACYTE, INC. shareholders approved Approval of amendment to the 2023 Equity Incentive Plan to increase the number of shares reserved for issuance by 3,500,000 at the 2026-06-10 meeting.
“The stockho lders approved the 2023 Plan Amendment.”
VERACYTE, INC. — fact timeline
Source-grounded facts extracted from VERACYTE, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VERACYTE, INC. shareholders approved Non-binding advisory vote on the compensation of the Company's named executive officers at the 2026-06-10 meeting.
“The stockho lders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”
VERACYTE, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026 at the 2026-06-10 meeting.
“The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
VERACYTE, INC. shareholders approved Election of nine directors to serve until the 2027 annual meeting of stockholders at the 2026-06-10 meeting.
“Each of the nine nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”
VERACYTE, INC. reported first quarter ended March 31, 2026 results: revenue $139.1 million, net income $28.7 million.
“Key Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period in 2025: • Increased total revenue by 21% to $139.1 million and testing revenue by 26% to $135.1 million, driven by Decipher growth of 30% to $86.5 million and Afirma growth of 21% to $46.4 million. • Increased total volume by 17% to 47,615 tests and testing volume by 19% to 45,248 tests, driven by Decipher growth of 24% to approximately 28,000 tests and Afirma growth of 12% to approximately 17,200 tests. • Recorded GAAP net income of $28.7 million, or 20.6% of revenue, and delivered adjusted EBITDA of $42.8 million, or 30.8% of revenue.”
Brent Shafer was appointed as Director at VERACYTE, INC..
“the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.”
Tom Miller was appointed as Director at VERACYTE, INC..
“the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.”
VERACYTE, INC. reported first quarter ended March 31, 2024 results: revenue $96.8 million, net income $1.9 million, EPS $0.02.
“EX-99.1 (EX-99.1 PRESS RELEASE 05.07.2024) --- PRESS RELEASE 05.07.2024 Document Exhibit 99.1 Veracyte Announces First Quarter 2024 Financial Results Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today”
VERACYTE, INC. reported financial results for the quarter and year ended December 31, 2023.
“On February 22, 2024, Veracyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report.”
John L. Bishop retired as Director at VERACYTE, INC..
“On February 7, 2024, John L. Bishop, a member of the Board of Directors (the “Board”) of Veracyte, Inc. (the “Company”), informed the Chair of the Board that he will retire at the end of his current term as director and not stand for reelection at the Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”).”
VERACYTE, INC. completed an acquisition involving C2i Genomics, Inc. for $70.0 million (closed 2024-02-05).
“On February 5, 2024 (the “Closing Date”), Veracyte, Inc., a Delaware corporation (“Veracyte”), completed its previously announced acquisition of C2i Genomics, Inc., a Delaware corporation (“C2i Genomics”), for a purchase price of $70.0 million”
VERACYTE, INC. reported full year 2024 results: revenue between $394 million and $402 million. Guidance initiated.
“Veracyte is initiating 2024 testing and product revenue guidance of 13% to 15% growth, partially offset by declining biopharma and other revenue, resulting in total company revenue growth of 10% to 12%, or $394 million to $402 million.”
VERACYTE, INC. reported the full year ended December 31, 2023 results: revenue between $358.0 million and $359.0 million.
“For the full year ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $358 million and $359 million, an increase of 21%”
VERACYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $95.0 million and $96.0 million.
“For the fourth quarter ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $95 million and $96 million, an increase of between 18% and 20%”
VERACYTE, INC. reported the third quarter ended September 30, 2023 results: revenue $90.1 million, net income Net loss for the third quarter of 2023 was $29.6 million, EPS $0.41.
“EX-99.1 (EX-99.1 PRESS RELEASE 11-07-2023) --- PRESS RELEASE 11-07-2023 Document Exhibit 99.1 Veracyte Announces Third Quarter 2023 Financial Results Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 7, 2023 --- Veracyte, Inc. (Nasdaq: VCYT)”
VERACYTE, INC. reported the second quarter ended June 30, 2023 results: revenue $90.3 million, net income Net loss for the second quarter of 2023 was $8.4 million, EPS Basic and diluted net loss per common share was $0.12.
“Second Quarter 2023 Financial Results Total revenue for the second quarter of 2023 was $90.3 million, an increase of 24% compared to $72.9 million reported in the second quarter of 2022. Testing revenue was $81.7 million, an increase of 37% compared to $59.7 million in the second quarter of 2022 driven primarily by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $4.0 million, an increase of 29% compared to $3.1 million in the second quarter of 2022. Biopharmaceutical and other revenue was $4.6 million, a decrease of 55% compared to $10.0 million in the second quarter of 2022. Total gross margin for the second quarter of 2023, including the amortization of acquired intangible assets, was 62%, compared to 59% in the second quarter of 2022. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 67%, compared to 66% in the second quarter of 2022. Operating expenses, excluding cost of r”
Tina S. Nova departed as General Manager, Urological Cancers at VERACYTE, INC..
“On August 4, 2023, the Company and Tina S. Nova, Ph.D. agreed that Dr. Nova will resign from her position as General Manager, Urological Cancers of the Company effective as of September 3, 2023”
VERACYTE, INC.: Amended and restated bylaws (Restated Bylaws) effective June 9, 2023, making changes consistent with the Declassification Amendment (effective 2023-06-09).
“On June 9, 2023, the Company’s amended and restated bylaws were amended and restated effective upon the filing and effectiveness of the Certificate of Amendment (the “Restated Bylaws”).”
VERACYTE, INC.: Stockholders approved Declassification Amendment to declassify the Board with conforming changes; Certificate of Amendment filed and effective June 9, 2023 (effective 2023-06-09).
“On June 9, 2023, the Company filed a certificate of amendment (the “Certificate of Amendment”) to the Current Charter that reflects the Declassification Amendment with the Delaware Secretary of State and the Certificate of Amendment became effective on filing.”
VERACYTE, INC. shareholders approved Approval of the Veracyte, Inc. 2023 Equity Incentive Plan at the 2023-06-08 meeting.
“on June 8, 2023, at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of Veracyte, Inc. (the “Company”), the Company’s stockholders approved the Company’s 2023 Equity Incentive Plan (the “2023 Plan”).”
VERACYTE, INC. reported the first quarter ended March 31, 2023 results: revenue $82.4 million, net income $8.1 million, EPS $0.11.
“EX-99.1 (EX-99.1 PRESS RELEASE 05.04.2023) --- PRESS RELEASE 05.04.2023 Document Exhibit 99.1 Veracyte Announces First Quarter 2023 Financial Results Grew Total Revenue to $82.4 million, an Increase of 22% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 4, 2023 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results”
VERACYTE, INC.: Amended and restated bylaws to conform to Delaware law changes and universal proxy rules, updating advance notice, proxy, and emergency provisions (effective 2023-02-09).
“On February 9, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”) and a periodic review of the bylaws of Veracyte, Inc. (“Veracyte”), Veracyte’s Board of Directors (the “Board”) approved and adopted Veracyte’s amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.”
Giulia C. Kennedy departed as Global Chief Scientific Officer and Chief Medical Officer at VERACYTE, INC..
“On December 9, 2022, Giulia C. Kennedy, Ph.D, Global Chief Scientific Officer and Chief Medical Officer of Veractye, Inc. (the “Company”), and the Company agreed that she would depart from the Company, effective December 31, 2022.”
VERACYTE, INC. reported the third quarter ended September 30, 2022 results: revenue $75.6 million, net income $8.7 million, EPS $0.12.
“Total revenue for the third quarter of 2022 was $75.6 million, an increase of 25% compared to $60.4 million in the third quarter of 2021. Testing revenue was $64.6 million, an increase of 27% compared to $50.9 million in the third quarter of 2021 driven primarily by the strong performance of our Decipher and Afirma tests. Product revenue was $3.3 million, an increase of 12% compared to $3.0 million in the third quarter of 2021. Biopharmaceutical and other revenue was $7.7 million, an increase of 18% compared to $6.5 million in the third quarter of 2021, driven primarily by the contribution of the HalioDx acquisition. Total gross margin for the third quarter of 2022, including the amortization of acquired intangible assets, was 59%, compared to 57% in the third quarter of 2021. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 66%, compared to 64% in the third quarter of 2021. Operating expenses, excluding cost of”
Eliav Barr, M.D. was appointed as Director at VERACYTE, INC..
“the Board appointed Eliav Barr, M.D., to serve as a director of the Company, effective immediately.”
Beverly Jane Alley departed as Vice President, Accounting at VERACYTE, INC..
“Ms. Alley’s service as Vice President, Accounting would continue through June 30, 2022, at which time, in exchange for a standard release of claims, she would depart from the Company and receive three months’ salary and continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.”
Beverly Jane Alley was appointed as Vice President, Accounting at VERACYTE, INC..
“In addition, effective February 22, 2022, Beverly Jane Alley, the Company’s Vice President and Chief Accounting Officer, was appointed the Company’s Vice President, Accounting.”
Jonathan Wygant was appointed as Vice President and Chief Accounting Officer at VERACYTE, INC..
“On February 22, 2022, Veracyte, Inc. (the “Company”) announced the appointment of Jonathan Wygant, 51, as its Vice President and Chief Accounting Officer.”
Tina S. Nova, Ph.D. was appointed as President of the Company’s CLIA U.S. business at VERACYTE, INC..
“On January 6, 2022, Veracyte, Inc. (the “Company”), announced certain key leadership promotions including the appointment of Tina S. Nova, Ph.D., to serve as President of the Company’s CLIA U.S. business, effective as of January 6, 2022.”
James H. Erlinger III retired as Executive Vice President, General Counsel and Secretary at VERACYTE, INC..
“On July 13, 2021, James H. Erlinger III, Executive Vice President, General Counsel and Secretary of Veracyte, Inc. (the “Company”), announced his retirement from the Company, effective as of July 31, 2021.”
Jane Alley departed as Acting Chief Financial Officer at VERACYTE, INC..
“Jane Alley, Acting Chief Financial Officer, would be resigning from her position as Acting Chief Financial Officer, effective as of July 19, 2021”
Rebecca Chambers was appointed as Chief Financial Officer at VERACYTE, INC..
“On July 12, 2021, Veracyte, Inc. (the “Company”) announced that it appointed Rebecca Chambers, 43, as Chief Financial Officer, effective as of July 19, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.